India Drug Makers Find Japan Market Entry Daunting Task
This article was originally published in PharmAsia News
India-based drug makers have encountered somewhat of a wall in trying to enter the Japanese pharmaceutical market, despite several major efforts over the past few years.
You may also be interested in...
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.